Carsgen announced 2023 interim results

Shanghai , aug. 22, 2023 /prnewswire/ -- carsgen therapeutics holdings limited (stock code: 2171.hk), a company focused on innovative car t-cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2023 interim results. business highlights collaboration agreement for zevor-cel commercialization in mainland china with huadong medicine.
MRNA Ratings Summary
MRNA Quant Ranking